LONDON --(BUSINESS WIRE)--Jun. 22, 2022-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its second-quarter 2022 results on Wednesday, August 3, 2022 at 1 p.m.   London time ( 8 a.m. EDT ).

LONDON --(BUSINESS WIRE)--Jun. 14, 2022-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced Peter Wilver has been elected to the Board of Directors, effective immediately. His election was part of the LivaNova 2022 Annual General Meeting of

LONDON --(BUSINESS WIRE)--May 25, 2022-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced Damien McDonald , Chief Executive Officer, will present in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference in Rancho Palos

LONDON --(BUSINESS WIRE)--May 4, 2022-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2022 . Financial Summary and Highlights 1 Worldwide sales were $240.2 million , a decrease of 3.0 percent on a

Intuitive monitor featuring patient-tailored approach is now in clinical use in select centers in U.S. and Europe LONDON --(BUSINESS WIRE)--Apr. 8, 2022-- LivaNova PLC (NASDAQ: LIVN), a market-leading medical technology and innovation company, today announced receipt of regulatory approvals and the

LONDON --(BUSINESS WIRE)--Mar. 24, 2022-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its first-quarter 2022 results on Wednesday, May 4, 2022 at 1 p.m.   London time ( 8 a.m. EDT ).

LONDON --(BUSINESS WIRE)--Mar. 14, 2022-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced the 250th unipolar depression patient has been implanted in the RECOVER clinical study , “A P r ospective, Multi-c e nter, Randomized C ontrolled

Study to evaluate effectiveness of hypoglossal nerve stimulation LONDON --(BUSINESS WIRE)--Feb. 24, 2022-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced the first patient implanted in the investigational device exemption (IDE) clinical

LONDON --(BUSINESS WIRE)--Feb. 23, 2022-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter and full year ended December 31, 2021 . For the fourth quarter of 2021, worldwide sales from continuing operations were $270.1

LONDON --(BUSINESS WIRE)--Jan. 12, 2022-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its fourth-quarter and full-year 2021 results on Wednesday, February 23, 2022 at 1 p.m.   London time ( 8 a.m. Eastern Time ).